Case Study:

Using AI in Precision Identification of Patients With Rare Diseases

AI-Powered Rare Disease Patient Identification and Diagnosis

Rare diseases offer diverse challenges. With Pharma offering rare disease medication, if you can find the patient, they will take your drug; however, finding the patient is the tricky part.

The Client Problem

The client had a rare disease drug with minimal competition.
    •    The illness is so rare, however, that the main difficulty was finding patients.
    •    Very few physicians were likely to come in contact with these patients.
    •    Finding these patients early is critical as the illness progresses.

The Solution

•    Certain facial traits were common to sufferers of the condition.
    •    Eularis created facial recognition software that identified patients with the condition
    •    It then crawled internet properties, (Facebook and Flickr etc), to find patients from online photos
    •    This allowed for faster identification and treatment before it was too late for these patients.
    •    However, due to sensitivity, the identification was addressed in a more palatable way.
    •    Once patients were identified, targeted advertising of keywords on Google PPC was prepared.
    •    Therefore, only when a search was conducted on the symptoms by the family, would this be activiated
    •    This triggered an ad leading them to our client’s website where they could self diagnose

The Outcome

Thirteen new patients were identified very rapidly. At a cost of $500,000/patient/year for the rest of their life, the ROI is undeniable.

To achieve these kinds of results, contact Eularis today.

Discover how AI can deliver growth for you.

Get Started Today!

Become A Member

Latest News

Read our latest blogs here.

Why Generative AI Prompts Fail

Dr Andree Bates

Introduction Generative AI is revolutionizing the pharmaceutical industry, offering unparalleled opportunities to accelerate drug discovery, optimize clinical trials, and refine patient care strategies. Yet, amidst

Read More »